Annual report pursuant to Section 13 and 15(d)

Organization, Plan of Business Operations (Details)

v3.22.1
Organization, Plan of Business Operations (Details)
$ / shares in Units, $ in Thousands
Feb. 08, 2019
USD ($)
$ / shares
shares
Feb. 15, 2022
Vote
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Nov. 12, 2018
USD ($)
Accumulated deficit     $ 76,999 $ 73,268  
Cash and cash equivalents     $ 3,763 $ 3,132  
Invagen Pharmaceuticals Inc          
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned         $ 35,000
Percentage of equity interest agreed to acquire in first stage         33.30%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount         $ 180,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares 5,833,333        
Business Acquisition, Share Price | $ / shares $ 6.00        
Business acquisition shares acquisition for net proceeds $ 31,500        
Invagen Pharmaceuticals Inc | Invagen Pharmaceuticals Inc          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%        
Subsequent Event          
Number of yes votes | Vote   8      
Number of no votes | Vote   14